- Home
- SLN vs OLMA Comparison
SLN vs OLMA Comparison
Compare SLN & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- OLMA
- Stock Information
- Founded
- SLN 1994
- OLMA 2006
- Country
- SLN United Kingdom
- OLMA United States
- Employees
- SLN N/A
- OLMA N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- SLN Health Care
- OLMA Health Care
- Exchange
- SLN Nasdaq
- OLMA Nasdaq
- Market Cap
- SLN 299.4M
- OLMA 299.7M
- IPO Year
- SLN N/A
- OLMA 2020
- Fundamental
- Price
- SLN $5.04
- OLMA $4.64
- Analyst Decision
- SLN Buy
- OLMA Strong Buy
- Analyst Count
- SLN 5
- OLMA 4
- Target Price
- SLN $32.60
- OLMA $24.50
- AVG Volume (30 Days)
- SLN 77.4K
- OLMA 452.7K
- Earning Date
- SLN 08-07-2025
- OLMA 08-12-2025
- Dividend Yield
- SLN N/A
- OLMA N/A
- EPS Growth
- SLN N/A
- OLMA N/A
- EPS
- SLN N/A
- OLMA N/A
- Revenue
- SLN $27,169,000.00
- OLMA N/A
- Revenue This Year
- SLN N/A
- OLMA N/A
- Revenue Next Year
- SLN N/A
- OLMA N/A
- P/E Ratio
- SLN N/A
- OLMA N/A
- Revenue Growth
- SLN 20.09
- OLMA N/A
- 52 Week Low
- SLN $1.97
- OLMA $2.86
- 52 Week High
- SLN $20.48
- OLMA $14.41
- Technical
- Relative Strength Index (RSI)
- SLN 33.31
- OLMA 45.46
- Support Level
- SLN $4.86
- OLMA $4.97
- Resistance Level
- SLN $6.40
- OLMA $5.66
- Average True Range (ATR)
- SLN 0.45
- OLMA 0.31
- MACD
- SLN -0.15
- OLMA -0.02
- Stochastic Oscillator
- SLN 10.92
- OLMA 19.05
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.